Information Provided By: 
Fly News Breaks for June 6, 2016
IPXL
Jun 6, 2016 | 07:22 EDT
Goldman analyst Stephan Stewart initiated Impax (IPXL) with a Sell and $33 price target. The analyst sees increasing competition to its largest on-market drug, generic Solaraze and tail risk that Endo's (ENDP) application for a label change on its second largest on-market drug, Opana ER, could result in the eventual removal of Impax's generic. The analyst adds, RenVela and Welchol expectations are reflected in valuation.
News For IPXL From the Last 2 Days
There are no results for your query IPXL
